Bristol Myers Squibb

@bmsnews

We work every day to transform patients’ lives through science. See our community guidelines: one.bms.com/3WHdbIG

New York, New York

Bristol Myers Squibb
@bmsnews
5h
#MEDIA: At #HCMSCHICAGO, we shared new positive 56-week results from our Phase 3 trial in pediatric patients living with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), reinforcing and building on previously reported findings: bit.ly/4zaupzp #AHA2026
Bristol Myers Squibb
@bmsnews
Oct 26
#MEDIA: Announcing results from a Phase 3 trial evaluating our investigational treatment for certain patients with EGFR-mutant non-squamous non-small cell lung cancer at #ESMO26. bit.ly/4jZfjc7
1
Bristol Myers Squibb
@bmsnews
Oct 23
#MEDIA: We’re presenting results from a Phase 1 trial evaluating #CARTCellTherapy in multiple sclerosis (MS) at #MSToronto2026: bit.ly/47V3NqZ
1
Bristol Myers Squibb
@bmsnews
Oct 23
#MEDIA: Announcing results from a Phase 3 trial evaluating our investigational treatment for certain adult patients with HR+/HER2- breast cancer at #ESMO26. bit.ly/4siOO3r
Bristol Myers Squibb
@bmsnews
Oct 22
Pleased to share our investigational cancer asset was recently awarded Best ADC Clinical Impact during the 13th Annual ADC Awards. This recognition is encouraging, particularly as we approach #ESMO26 where we’ll be presenting data on our ADC asset: bit.ly/4i92P0d

Bristol Myers Squibb’s posts